Key facts
- ViroMissile’s last known valuation is $100.0M (Dec 2023).
- It has raised $15.5M across 1 recorded rounds; the latest was Seed Round ($500K) in Mar 2025.
- 1 investment vehicle was formed to buy ViroMissile shares in the last 12 months, reporting $169K sold to 13 investors, per SEC Form D filings.
- ViroMissile has filed 4 Form Ds with the SEC since 2023, most recently Jun 2025 ($500K sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for ViroMissile
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy ViroMissile shares, reporting $169K sold to 13 investors. Most recent filing May 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About ViroMissile
Developer of medical cures designed to provide treatment for cancer. The company utilizes oncologic viruses to specifically target and destroy tumor cells with precision and effectiveness, creating an approach capable of eliminating tumors with a single treatment and surpassing the limitations of current methods, enabling clients to access more advanced and streamlined cancer care.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2016
- Website
- viromissile.com/
- Ownership
- Privately Held (backing)
ViroMissile doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ViroMissile shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ViroMissile in its N-PORT filings yet. We sweep new filings monthly.